Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the transaction, the chief executive officer now owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Nkarta Stock Performance
Shares of NASDAQ NKTX opened at $2.47 on Monday. The company has a market cap of $174.31 million, a PE ratio of -1.31 and a beta of 0.85. The firm’s 50 day moving average price is $2.52 and its 200-day moving average price is $4.18. Nkarta, Inc. has a 52-week low of $2.08 and a 52-week high of $16.24.
Institutional Trading of Nkarta
Institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH purchased a new position in shares of Nkarta in the third quarter worth $33,000. GAMMA Investing LLC increased its holdings in Nkarta by 110.9% in the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after buying an additional 5,243 shares in the last quarter. Forefront Analytics LLC purchased a new position in Nkarta in the 2nd quarter worth about $70,000. Intech Investment Management LLC bought a new position in Nkarta during the 3rd quarter valued at about $74,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Nkarta during the 3rd quarter valued at about $93,000. 80.54% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on NKTX
Nkarta Company Profile
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
See Also
- Five stocks we like better than Nkarta
- Investing in Construction Stocks
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Oilfield Leader SLB: An AI Name You Need to Know
- The Basics of Support and Resistance
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.